Abstract
Murine monoclonal antibodies that bind selectively to adducts formed on DNA by the antitumor drug cis-diamminedichloroplatinum(II), cis-DDP, or to the chemotherapeutically inactive trans isomer trans-DDP were elicited by immunization with calf thymus DNA modified with either cis- or trans-DDP at ratios of bound platinum per nucleotide, (D/N)b, of 0.06-0.08. The binding of two monoclonal antibodies to cis-DDP-modified DNA was competitively inhibited (50% control) in an enzyme-linked immunosorbent assay (ELISA) by 4-6 nM concentrations (600-900 fmol) of cis-DDP bound to DNA, (D/N)b = 0.031. Similar concentrations (4-6 nM) of cis-DDP-modified poly(dG).poly(dC) also inhibited antibody binding, whereas higher concentrations (17-36 nM) of cis-DDP-modified poly[d(AG)].poly[d(TC)] were required for inhibition. Adducts formed by cis-DDP on other synthetic DNA polymers did not inhibit antibody binding to cis-DDP-DNA. The biologically active compounds [Pt(en)Cl2], [Pt(dach)Cl2], and [Pt(NH3)2(cbdca)] (carboplatin) (where en is ethylenediamine, dach is 1,2-diaminocyclohexane, and cbdca is cyclobutane-1,1-dicarboxylate) all formed antibody-detectable adducts on DNA, whereas the inactive platinum complexes trans-DDP and [Pt(dien)Cl]Cl (dien, diethylenetriamine) did not. The monoclonal antibodies therefore recognize a bifunctional Pt-DNA adduct with cis stereochemistry in which platinum is coordinated by two adjacent guanines or, to a lesser degree, by adjacent adenine and guanine. A monoclonal antibody raised against trans-DDP-DNA was competitively inhibited in an ELISA by 40 nM trans-DDP bound to DNA, (D/N)b = 0.022. This antibody crossreacted with unmodified, denatured DNA. Its binding to trans-DDP-DNA was selectively inhibited by trans-DDP-modified poly[d(GT)].poly[d(CA)] (50% inhibition at 1 nM bound trans-DDP). The recognition of cis- or trans-DDP-modified DNAs by monoclonal antibodies thus parallels the known modes of DNA binding of these compounds and may correlate with their biological activities.
MeSH Terms
Animals
Antibodies, Monoclonal/immunology
Antibody Formation
Base Sequence
Cisplatin
DNA/immunology
DNA Damage
Epitopes
Isomerism
Mice
Structure-Activity Relationship
Chemicals
Antibodies, Monoclonal
Epitopes
DNA
Cisplatin
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Sundquist W I
Department of Chemistry, Massachusetts Institute of Technology, Cambridge 02139.
Lippard S J
Stollar B D
References (18)
18 references, click to expand
-
Physicochemical studies on polydeoxyribonucleotides containing defined repeating nucleotide sequences.
J Mol Biol. 1970 Dec 28;54(3):465-97
PMID: 5492018
-
Comparison between poly(dG-dC).poly(dG-dC) and DNA modified by cis-diamminedichloroplatinum (II): immunological and spectroscopic studies.
J Biomol Struct Dyn. 1985 Oct;3(2):363-75
PMID: 3917027
-
Immunochemical studies of DNA modified by cis-dichlorodiammineplatinum(II) in vivo and in vitro.
Cancer Res. 1981 Oct;41(10):4127-31
PMID: 7197193
-
Preparation of monoclonal antibodies: strategies and procedures.
Methods Enzymol. 1981;73(Pt B):3-46
PMID: 7300683
-
Antibodies elicited against cis-diamminedichloroplatinum(II)-modified DNA are specific for cis-diamminedichloroplatinum(II)-DNA adducts formed in vivo and in vitro.
Proc Natl Acad Sci U S A. 1982 Nov;79(21):6443-7
PMID: 6959129
-
Immunoassay of carcinogen-modified DNA.
Prog Nucleic Acid Res Mol Biol. 1984;31:1-58
PMID: 6085171
-
The quantitative detection of various Pt-DNA-adducts in Chinese hamster ovary cells treated with cisplatin: application of immunochemical techniques.
Carcinogenesis. 1985 Apr;6(4):561-6
PMID: 4039227
-
Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation.
Biochemistry. 1985 Jan 29;24(3):707-13
PMID: 4039603
-
Sequence-dependent termination of in vitro DNA synthesis by cis- and trans-diamminedichloroplatinum (II).
Proc Natl Acad Sci U S A. 1985 Jul;82(14):4616-9
PMID: 3895221
-
Binding of the antitumor drug cis-diamminedichloroplatinum(II) (cisplatin) to DNA.
Biochim Biophys Acta. 1985;780(3):167-80
PMID: 3896310
-
Quantitation of cis-diamminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy.
J Clin Invest. 1986 Feb;77(2):545-50
PMID: 3944268
-
Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA.
Cancer Res. 1986 Apr;46(4 Pt 2):1972-9
PMID: 3512077
-
Binding of cis- and trans-diamminedichloroplatinum(II) to deoxyribonucleic acid exposes nucleosides as measured immunochemically with anti-nucleoside antibodies.
Biochemistry. 1986 Apr 8;25(7):1520-4
PMID: 3707890
-
Chemical reactivity of monofunctional platinum-DNA adducts.
Biochemistry. 1986 Aug 12;25(16):4534-9
PMID: 3768295
-
Interactions of the antitumour drug cisplatin with DNA in vitro and in vivo.
IARC Sci Publ. 1986;(78):83-99
PMID: 3294590
-
Interaction of trans-diamminedichloroplatinum(II) with DNA: formation of monofunctional adducts and their reaction with glutathione.
Biochemistry. 1987 Jun 16;26(12):3303-7
PMID: 3651385
-
Synthesis and 1H NMR spectroscopic characterization of trans-[Pt(NH3)2[d(ApGpGpCpCpT)-N7-A(1),N7-G(3)]].
Biochemistry. 1987 Sep 8;26(18):5651-7
PMID: 3676275
-
Resolution of alpha, beta and gamma DNA of Saccharomyces cerevisiae with the antitumor drug cis-Pt (NH3)2CL2. Evidence for preferential drug binding by GpG sequences of DNA.
J Mol Biol. 1976 Jul 15;104(4):793-801
PMID: 785014